Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study

BACKGROUND: Assessing the safety of SARS-CoV-2 mRNA vaccines and the effect of immunotherapies on the seroconversion rate in patients with autoimmune neurological conditions (ANC) is relevant to clinical practice. Our aim was to assess the antibody response to and safety of SARS-CoV-2 mRNA vaccines...

Descripción completa

Detalles Bibliográficos
Autores principales: Giannoccaro, Maria Pia, Vacchiano, Veria, Leone, Marta, Camilli, Federico, Zenesini, Corrado, Panzera, Ivan, Balboni, Alice, Tappatà, Maria, Borghi, Annamaria, Salvi, Fabrizio, Lugaresi, Alessandra, Rinaldi, Rita, Di Felice, Giulia, Lodi, Vittorio, Lazzarotto, Tiziana, Liguori, Rocco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063626/
https://www.ncbi.nlm.nih.gov/pubmed/35503375
http://dx.doi.org/10.1007/s00415-022-11142-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063626/
https://www.ncbi.nlm.nih.gov/pubmed/35503375
http://dx.doi.org/10.1007/s00415-022-11142-7

Ejemplares similares